Sharemaestro Newsreel

(URGN) Volatility Zones as Tactical Triggers

This article from Stock Traders Daily discusses Urogen Pharma Ltd. (NASDAQ: URGN) and presents AI-generated trading strategies based on volatility zones. It highlights strong sentiment across all time horizons supporting an overweight bias, notes the absence of resistance levels above the current price, and …

Alto Neuroscience (NYSE:ANRO) Trading 8% Higher Following Earnings Beat

Alto Neuroscience (NYSE:ANRO) shares rose 8% after reporting a quarterly loss of $0.65 per share, surpassing the consensus estimate of a $0.73 loss. Analysts maintain a "Moderate Buy" consensus rating with an average price target of $36.62, and institutional investors like Commodore Capital and …

Abeona Therapeutics (ABEO) Stock Dips After Q2 Miss; Price-to-Sa

Ovid Therapeutics Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026

Stock Traders Purchase Large Volume of Eyepoint Pharmaceuticals Put Options (NASDAQ:EYPT)

Bio-Techne (NASDAQ:TECH) Downgraded to Equal Weight Rating by Wells Fargo & Company

European Equities Traded in the US Rise in Thursday Trading

European equities traded in the US as American depositary receipts were higher late Thursday morning, rising 0.45% to 1,969.72 on the S&P Europe Select ADR Index. From continental Europe, the gainers were led by biopharmaceutical company Cellectis (CLLS) and biotech firm Evaxion Silver Upgrade …

Form 8K ABVC Biopharma Inc For: 12 August By Investing.com

This article reports on ABVC Biopharma Inc.'s Form 8K filing for August 12. The filing is a standard requirement for publicly traded companies to announce significant events that shareholders should know. The article provides the title of the filing and mentions the company's stock …

Absci Corp. Earnings Call Highlights ABS-201 And Cash

Absci Corp.'s Q2 earnings call highlighted promising interim Phase I data for its flagship antibody ABS-201, showing favorable safety, tolerability, and a long half-life. The company's financial position has been significantly strengthened by a recent $100 million financing, including a $40 million strategic investment …

Alpha Cognition (ACOG) doubles H1 2026 revenue as cash burn accelerates

Alpha Cognition Inc. (ACOG) reported significant revenue growth in Q2 2026 and H1 2026, driven by strong sales of its Alzheimer's drug ZUNVEYL, with Q2 revenue up 283% year-over-year and H1 revenue up 110%. Despite this, the company remains unprofitable with a net loss …

Stifel raises LB Pharmaceuticals stock price target on pipeline outlook

Stifel has raised its price target for LB Pharmaceuticals Inc (NASDAQ:LBRX) shares to $53 from $40, maintaining a Buy rating, citing expanded indication plans for its lead compound LB-102 in Alzheimer’s and schizophrenia. The company is conducting a phase 3 study for LB-102 with …

Altimmune, Inc. Q2 2026: Revenue $0 EPS $(0.12) — 10-Q Summary

Altimmune, Inc. reported its second-quarter 2026 results, showing no revenue and a net loss of $(22.83M), with diluted loss per share at $(0.12). This represents an improvement in EPS compared to $(0.27) in Q2 2025. Key business highlights include the start of the PERFORMA …

Allogene Therapeutics, Inc. Announces Cemacabtagene Ansegedleucel (Cema-Cel) Is Being Evaluated in Alpha3, the First Pivotal, Randomized Phase 2 Trial in LBCL

Allogene Therapeutics announced that cemacabtagene ansegedleucel (cema-cel) is being evaluated in ALPHA3, a pivotal Phase 2 trial for high-risk Large B-Cell Lymphoma (LBCL) patients. The trial aims to assess if MRD-guided treatment can delay or prevent relapse, with early data showing favorable MRD negativity …

CCORF Maintains Rocket Pharmaceuticals(RCKT.US) With Buy Rating, Maintains Target Price $10

CCORF has reiterated its Buy rating for Rocket Pharmaceuticals (RCKT.US) and maintained a target price of $10. This indicates a continued positive outlook on the company's stock performance by the firm.

Relay Therapeutics Stock Is Up Nearly 500% Over the Past Year

Relay Therapeutics (RLAY), a clinical-stage precision medicines company in targeted oncology with a $4.4 billion market cap, has seen its stock surge by 486% over the past year, trading near a new 3-year high. While technical momentum is strong with a 100% "Buy" opinion …

XBiotech (NASDAQ: XBIT) trims R&D spend yet remains loss-making in Q2 2026

XBiotech Inc. reported a Q2 2026 net loss of $6.7 million and a six-month net loss of $12.2 million, despite significantly reducing research and development and general and administrative expenses. The clinical-stage biopharmaceutical company does not anticipate generating revenue in 2026 and expects continued …

Insider Move: Corey M. Watton Exercises Options, Realizing $77K At Zevra Therapeutics

Corey M. Watton, a Director at Zevra Therapeutics (NASDAQ: ZVRA), exercised stock options for 12,300 shares, valued at $77,859, according to a recent SEC filing. The company's financials show a positive revenue trend with 53.25% growth, a high gross margin of 96.16%, but a …

Silence Therapeutics (SLN): Invus and Avicenna entities report 7.0% stake via Debbane

Invus Public Equities, L.P. and Avicenna Life Sci Master Fund LP have filed an updated ownership report for Silence Therapeutics plc (SLN). As of June 30, 2026, entities related to Invus beneficially held 6.1% of ordinary shares, and Avicenna-related entities held 0.9%, with Raymond …

Massachusetts Biotech's Flagship Gene Therapy Posts Fifth Straight Quarterly Decline as Muscular Dystrophy Data Loom

Sarepta Therapeutics (SRPT) saw its flagship gene therapy, ELEVIDYS, experience a fifth consecutive quarterly revenue decline, with analysts from H.C. Wainwright & Co. reiterating a Sell rating and a $5.00 price target. Despite this, the market reaction was muted, suggesting investors are assigning significant …

CorMedix Q2 Earnings Call Highlights

High Risk, High Reward: 3 Healthcare Stocks to Watch in 2026 CorMedix (NASDAQ:CRMD) reported second-quarter 2026 consolidated revenue of $101.9 million and adjusted EBITDA of $58.7 million, while reaffirming its full-year revenue outlook and raising adjusted EBITDA guidance. The company also said it signed …

MacroGenics: Q2 Earnings Snapshot

MacroGenics Inc. (MGNX) reported second-quarter earnings of $19.5 million, or 31 cents per share, significantly exceeding Wall Street's expectation of a 40-cent loss per share. However, the biopharmaceutical company's revenue of $32.8 million fell short of the $44 million forecast by analysts. The earnings …

CorMedix CEO Expects Supplemental Filing For Fungal Disease Treatment By Q3 – CRMD Stock Sees Best Day In Nearly 10 Months After Earnings Beat

Cocrystal Pharma Q2 Results: EPS Loss Widens to $(0.23), Misses Estimate

CorMedix Stock Jumps on Strong DefenCath Sales

Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM) Targets Disability Drivers Beyond Relapse Rates in Multiple

Abeona Therapeutics earnings missed by $0.13, revenue fell short of estimates

Polaryx Therapeutics, Inc. (NASDAQ:PLYX) Given Average Recommendation of "Moderate Buy" by Brokerages

Polaryx Therapeutics (NASDAQ:PLYX) has received a "Moderate Buy" consensus recommendation from brokerages, with an average 12-month price target of $7.67 against a current share price of $2.48. Insider ownership is significant at 45.82%, and CEO Alex Keun Mo Yang recently purchased 88,453 shares. The …

Spruce Biosciences (NASDAQ:SPRB) Given New $144.00 Price Target at Citizens Jmp

Citizens Jmp has reduced its price target for Spruce Biosciences (NASDAQ:SPRB) to $144.00 from $150.00 but maintained a "market outperform" rating, indicating a potential upside of nearly 199%. Despite a wider-than-expected quarterly loss of $6.68 per share, analyst sentiment remains largely positive with a …

Longeveron Inc. (LGVN) investors disclose 9% beneficial stake through warrant holdings

Mitchell P. Kopin, Daniel B. Asher, and Intracoastal Capital LLC have filed an amended Schedule 13G, disclosing a beneficial ownership of approximately 9.0% in Longeveron Inc.'s Class A common stock. This stake, totaling 2,941,180 shares, is primarily held through warrants exercisable by Intracoastal Capital. …

ArriVent BioPharma (NASDAQ:AVBP) Shares Down 4.7% Following Weak Earnings

ArriVent BioPharma (NASDAQ:AVBP) experienced a 4.7% drop in share price after reporting weaker-than-expected quarterly earnings, missing analyst estimates by $0.06 with a $1.05-per-share loss. Despite the share price decline and significantly lower trading volume, analyst sentiment remains largely positive, holding a "Moderate Buy" consensus …

Kyverna Therapeutics advances autoimmune drug mivocabtagene autoleucel with strong trial results and regulatory progress.

Kyverna Therapeutics is making significant progress with its autoimmune drug, mivocabtagene autoleucel, showing strong trial results where all 26 patients stopped chronic immunotherapies and most reported improved mobility. The company is pursuing a rolling Biologics License Application, aiming for completion by late 2026 and …

Artelo Biosciences (ARTL) investors disclose 4.8% stake via Intracoastal warrant

Mitchell P. Kopin, Daniel B. Asher, and Intracoastal Capital LLC have disclosed a 4.8% beneficial ownership stake in Artelo Biosciences (ARTL) through a warrant held by Intracoastal. This ownership amounts to 173,914 shares of common stock, issuable upon the warrant's exercise, and is based …

AQR Capital discloses 5.82% Vanda Pharmaceuticals (VNDA) ownership on 13G

AQR Capital Management, LLC and AQR Capital Management Holdings, LLC have disclosed a passive ownership stake of 5.82% in Vanda Pharmaceuticals Inc. (VNDA), amounting to 3,497,695 shares. The SEC filing, a Schedule 13G, indicates that these entities have shared voting power over 3,313,298 shares …

Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) Given Consensus Rating of "Moderate Buy" by Brokerages

Vanda Pharmaceuticals (NASDAQ:VNDA) has received a consensus "Moderate Buy" rating from eight brokerages, with an average 12-month price target of $13.70 despite recent reductions from some analysts. The company reported a larger-than-expected quarterly loss and missed revenue estimates, leading analysts to anticipate unprofitability for …

Invus reports 8.0% stake in Scholar Rock (SRRK) through 9.6M shares

Invus Public Equities, L.P. and associated entities have reported an 8.0% beneficial ownership stake in Scholar Rock Holding Corporation (SRRK), totaling 9,575,013 shares of common stock. This is detailed in an amended Schedule 13G filing, which states that the shares were acquired for passive …

Abivax S.A. (ABVX) investors report 6.0% beneficial stake via Invus entities

Invus Public Equities, L.P. and affiliated entities, including Avicenna Life Sci Master Fund LP, have collectively reported a 6.0% beneficial ownership in Abivax S.A. (ABVX) as of June 30, 2026. This stake, comprising Ordinary Shares and American Depositary Shares, totals 4,825,759 shares attributed to …